Top Tweets for #TrueMRD

4 months ago

We received Medicare coverage for our #TrueMRD Monitoring Test for patients with muscle-invasive bladder cancer (MIBC). Available for clinicians to order on June 1, 2026, this marks the commercial launch of Veracyte's first molecular residual disease (#MRD) offering and the only commercially available truly whole-genome MRD test to come to market. 🔗 Read the full press release - https://t.co/AoRjV488BX 🔗 Learn about the TrueMRD Monitoring Test for MIBC - https://t.co/THT5ejW7Nn #MuscleInvasiveBladderCancer #BladderCancer #WholeGenomeSequencing $VCYT Disclaimer - https://t.co/fQcKkGFugi

Veracyte's tweet photo. We received Medicare coverage for our #TrueMRD Monitoring Test for patients with muscle-invasive bladder cancer (MIBC).

Available for clinicians to order on June 1, 2026, this marks the commercial launch of Veracyte's first molecular residual disease (#MRD) offering and the only commercially available truly whole-genome MRD test to come to market.

🔗 Read the full press release - https://t.co/AoRjV488BX

🔗 Learn about the TrueMRD Monitoring Test for MIBC - https://t.co/THT5ejW7Nn

#MuscleInvasiveBladderCancer #BladderCancer #WholeGenomeSequencing $VCYT

Disclaimer - https://t.co/fQcKkGFugi

220

Veracyte, Inc.

@Veracyte

9 months ago

LIVE WEBINAR - Dec 5: Phillip G. Febbo, MD, as he introduces our Veracyte #TrueMRD platform and its utility in tumor-informed circulating tumor DNA (ctDNA) analysis for monitoring minimal residual disease (#MRD), treatment response, and clonal evolution. Gain insights into how WGS-based ctDNA profiling enables: 🔹 Earlier detection of disease recurrence 🔹 Sensitive MRD monitoring 🔹 Deeper whole-genome insights 🔹 More personalized drug development and patient management 📅 Dec 5 | 10am PT / 1pm ET 🔗 Register now: https://t.co/1BGzbpIABQ #ctDNA #LiquidBiopsy #PrecisionMedicine #ClinicalTrials

Veracyte's tweet photo. LIVE WEBINAR - Dec 5: Phillip G. Febbo, MD, as he introduces our Veracyte #TrueMRD platform and its utility in tumor-informed circulating tumor DNA (ctDNA) analysis for monitoring minimal residual disease (#MRD), treatment response, and clonal evolution.

Gain insights into how WGS-based ctDNA profiling enables:
🔹 Earlier detection of disease recurrence
🔹 Sensitive MRD monitoring
🔹 Deeper whole-genome insights
🔹 More personalized drug development and patient management

📅 Dec 5 | 10am PT / 1pm ET
🔗 Register now: https://t.co/1BGzbpIABQ

#ctDNA #LiquidBiopsy #PrecisionMedicine #ClinicalTrials

144

Top Tweets for #TrueMRD

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users